390 related articles for article (PubMed ID: 20118981)
1. Opposing effects of hMOF and SIRT1 on H4K16 acetylation and the sensitivity to the topoisomerase II inhibitor etoposide.
Hajji N; Wallenborg K; Vlachos P; Füllgrabe J; Hermanson O; Joseph B
Oncogene; 2010 Apr; 29(15):2192-204. PubMed ID: 20118981
[TBL] [Abstract][Full Text] [Related]
2. Modulations of hMOF autoacetylation by SIRT1 regulate hMOF recruitment and activities on the chromatin.
Lu L; Li L; Lv X; Wu XS; Liu DP; Liang CC
Cell Res; 2011 Aug; 21(8):1182-95. PubMed ID: 21502975
[TBL] [Abstract][Full Text] [Related]
3. Histone acetyltransferase hMOF promotes S phase entry and tumorigenesis in lung cancer.
Zhao L; Wang DL; Liu Y; Chen S; Sun FL
Cell Signal; 2013 Aug; 25(8):1689-98. PubMed ID: 23628702
[TBL] [Abstract][Full Text] [Related]
4. Arsenic Trioxide Reduces Global Histone H4 Acetylation at Lysine 16 through Direct Binding to Histone Acetyltransferase hMOF in Human Cells.
Liu D; Wu D; Zhao L; Yang Y; Ding J; Dong L; Hu L; Wang F; Zhao X; Cai Y; Jin J
PLoS One; 2015; 10(10):e0141014. PubMed ID: 26473953
[TBL] [Abstract][Full Text] [Related]
5. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
Marchion DC; Bicaku E; Turner JG; Daud AI; Sullivan DM; Munster PN
Clin Cancer Res; 2005 Dec; 11(23):8467-75. PubMed ID: 16322310
[TBL] [Abstract][Full Text] [Related]
6. Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells.
Barbetti V; Gozzini A; Cheloni G; Marzi I; Fabiani E; Santini V; Dello Sbarba P; Rovida E
Epigenetics; 2013 Feb; 8(2):210-9. PubMed ID: 23321683
[TBL] [Abstract][Full Text] [Related]
7. Additive effects of histone deacetylase inhibitors and amphetamine on histone H4 acetylation, cAMP responsive element binding protein phosphorylation and DeltaFosB expression in the striatum and locomotor sensitization in mice.
Shen HY; Kalda A; Yu L; Ferrara J; Zhu J; Chen JF
Neuroscience; 2008 Dec; 157(3):644-55. PubMed ID: 18848971
[TBL] [Abstract][Full Text] [Related]
8. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid.
Marchion DC; Bicaku E; Daud AI; Richon V; Sullivan DM; Munster PN
J Cell Biochem; 2004 May; 92(2):223-37. PubMed ID: 15108350
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide.
Keshelava N; Davicioni E; Wan Z; Ji L; Sposto R; Triche TJ; Reynolds CP
J Natl Cancer Inst; 2007 Jul; 99(14):1107-19. PubMed ID: 17623797
[TBL] [Abstract][Full Text] [Related]
10. Measurement of the cellular deacetylase activity of SIRT1 on p53 via LanthaScreen® technology.
Robers MB; Loh C; Carlson CB; Yang H; Frey EA; Hermanson SB; Bi K
Mol Biosyst; 2011 Jan; 7(1):59-66. PubMed ID: 20931131
[TBL] [Abstract][Full Text] [Related]
11. The synergistic effects of DNA-damaging drugs cisplatin and etoposide with a histone deacetylase inhibitor valproate in high-risk neuroblastoma cells.
Groh T; Hrabeta J; Khalil MA; Doktorova H; Eckschlager T; Stiborova M
Int J Oncol; 2015 Jul; 47(1):343-52. PubMed ID: 25963435
[TBL] [Abstract][Full Text] [Related]
12. Expression of hMOF, but not HDAC4, is responsible for the global histone H4K16 acetylation in gastric carcinoma.
Zhu L; Yang J; Zhao L; Yu X; Wang L; Wang F; Cai Y; Jin J
Int J Oncol; 2015; 46(6):2535-45. PubMed ID: 25873202
[TBL] [Abstract][Full Text] [Related]
13. hMOF histone acetyltransferase is required for histone H4 lysine 16 acetylation in mammalian cells.
Taipale M; Rea S; Richter K; Vilar A; Lichter P; Imhof A; Akhtar A
Mol Cell Biol; 2005 Aug; 25(15):6798-810. PubMed ID: 16024812
[TBL] [Abstract][Full Text] [Related]
14. Differential sensitivity of human leukemic cell lines to the histone deacetylase inhibitor, trichostatin A.
Ninios YP; Sekeri-Pataryas KE; Sourlingas TG
Leuk Res; 2010 Jun; 34(6):786-92. PubMed ID: 19782399
[TBL] [Abstract][Full Text] [Related]
15. In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates.
Marchion DC; Bicaku E; Daud AI; Sullivan DM; Munster PN
Mol Cancer Ther; 2005 Dec; 4(12):1993-2000. PubMed ID: 16373714
[TBL] [Abstract][Full Text] [Related]
16. The histone deacetylase inhibitor trichostatin A downregulates human MDR1 (ABCB1) gene expression by a transcription-dependent mechanism in a drug-resistant small cell lung carcinoma cell line model.
El-Khoury V; Breuzard G; Fourré N; Dufer J
Br J Cancer; 2007 Aug; 97(4):562-73. PubMed ID: 17667922
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage.
Solomon JM; Pasupuleti R; Xu L; McDonagh T; Curtis R; DiStefano PS; Huber LJ
Mol Cell Biol; 2006 Jan; 26(1):28-38. PubMed ID: 16354677
[TBL] [Abstract][Full Text] [Related]
18. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors.
Zhu WG; Lakshmanan RR; Beal MD; Otterson GA
Cancer Res; 2001 Feb; 61(4):1327-33. PubMed ID: 11245429
[TBL] [Abstract][Full Text] [Related]
19. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
20. HSP72 functionally inhibits the anti-neoplastic effects of HDAC inhibitors.
Fujii K; Suzuki N; Jimura N; Idogawa M; Kondo T; Iwatsuki K; Kanekura T
J Dermatol Sci; 2018 Apr; 90(1):82-89. PubMed ID: 29395577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
